according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014
SECTION	1: Identification of	the substance/mixt	ure and of the company/undertaking

### **1.1 Product identifier**

Trade name : Ezetimibe / Atorvastatin Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-	:	Pharmaceutical
stance/Mixture		

### 1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A
Telephone	:	551-430-6000
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

### **1.4 Emergency telephone number**

215-631-6999

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2 Long-term (chronic) aquatic hazard, Category 2 H373: May cause damage to organs through prolonged or repeated exposure. H411: Toxic to aquatic life with long lasting effects.

### 2.2 Label elements

Labelling (REGULATION Hazard pictograms	(EC) :	No 1272/2008)
Signal word	:	Warning
Hazard statements	:	<ul><li>H373 May cause damage to organs through prolonged or repeated exposure.</li><li>H411 Toxic to aquatic life with long lasting effects.</li></ul>
Precautionary statements	:	Prevention:P260Do not breathe dust.P273Avoid release to the environment.



according to Regulation (EC) No. 1907/2006

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014

### **Response:**

P314 Get medical advice/ attention if you feel unwell.

P391 Collect spillage.

### Hazardous components which must be listed on the label:

Atorvastatin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

#### Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Atorvastatin	134523-03-8	STOT RE 2; H373 (Liver, muscle) Aquatic Chronic 2; H411	>= 10 - < 20
Ezetimibe	163222-33-1	Aquatic Chronic 1; H410	>= 2.5 - < 10
		M-Factor (Chronic aquatic toxicity): 1	

For explanation of abbreviations see section 16.

2

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures


General advice

In the case of accident or if you feel unwell, seek medical advice immediately.

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		DS Number: 6489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
			When symptoms advice.	persist or in all cases of doubt seek medical	
Protection of first-aiders		:	First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
lf inh	If inhaled		If inhaled, remove Get medical atter	e to fresh air. ntion if symptoms occur.	
In ca	se of skin contact	:	Wash with water Get medical atter	and soap. ntion if symptoms occur.	
In ca	se of eye contact	:	If in eyes, rinse w Get medical atter	vell with water. ntion if irritation develops and persists.	
lf swa	allowed	:	Get medical atter	NOT induce vomiting. ntion if symptoms occur. roughly with water.	
4.2 Most	important symptoms a	nd e	effects, both acut	e and delayed	
Risks	5	:	May cause dama exposure.	ge to organs through prolonged or repeated	
			the skin.	t can cause mechanical irritation or drying of the eyes can lead to mechanical irritation.	
4.3 Indica	ation of any immediate	me	dical attention an	d special treatment needed	
	tment	:		ically and supportively.	
SECTIO	N 5: Firefighting mea	sur	es		
5.1 Exting	guishing media				
Suita	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ( Dry chemical		
Unsu medi	iitable extinguishing a	: None known.			
5.2 Speci	al hazards arising from	) the	e substance or mi	xture	
-	cific hazards during fire-	:	Avoid generating concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a	
Haza ucts	ardous combustion prod-	:	Carbon oxides Nitrogen oxides (	NOx)	





## **Ezetimibe / Atorvastatin Formulation**

Vers 2.6	sion	Revision Date: 09.04.2021		DS Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
				Fluorine compour Metal oxides	nds
5.3 Advice for firefighters Special protective equipment for firefighters		:		e, wear self-contained breathing apparatus. tective equipment.	
Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to d so. Evacuate area.		

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.	
	Follow safe handling advice (see section 7) and persona	al pro-
	tective equipment recommendations (see section 8).	

### 6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal.</li> <li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li> <li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>
-------------------------	--

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures

: Static electricity may accumulate and ignite suspended dust

according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014		
Local/Total ventilation Advice on safe handling		<ul> <li>Provide adea and bonding</li> <li>Use only wit</li> <li>Do not breat Do not swall</li> <li>Avoid contac Avoid prolon</li> <li>Handle in ac practice, bas sessment</li> <li>Minimize dua Keep contain Keep away f</li> <li>Take precau</li> </ul>	Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to t		
Hyç	jiene measures	flushing syst place. When nated clothin The effective engineering appropriate industrial hys	o chemical is likely during typical use, provide eye ems and safety showers close to the working using do not eat, drink or smoke. Wash contami- ng before re-use. e operation of a facility should include review of controls, proper personal protective equipment, degowning and decontamination procedures, giene monitoring, medical surveillance and the histrative controls.		
7.2 Con	ditions for safe storage,	including any in	compatibilities		
	quirements for storage as and containers		perly labelled containers. Store in accordance with r national regulations.		
Adv	vice on common storage	ge : Do not store with the following product types: Strong oxidizing agents			
7.3 Spe	cific end use(s)				
•		· No data ava	ilable		


Specific use(s)	:	No data available
-----------------	---	-------------------

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL		
		Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used				
Atorvastatin	134523-03- 8	TWA	0.05 mg/m3 (OEB 3)	Internal		
		Wipe limit	0.5 mg/100 cm <sup>2</sup>	Internal		
Ezetimibe	163222-33-	TWA	25 µg/m3 (OEB 3)	Internal		





## Ezetimibe / Atorvastatin Formulation

Ver 2.6	sion Revision D 09.04.202		8 Number: 39-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
		1			
			Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
	Magnesium stea-	557-04-0	OELV - 8 hrs	10 mg/m3	IE OEL
	rate		(TWA)		
		Further information: Where no specific short-term exposure limit is listed, a			
		figure three times the long-term exposure limit value should be used			

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipme	ht	
Eye protection	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.	
Hand protection		
Material	Chemical-resistant gloves	
Remarks Skin and body protection Respiratory protection	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. If adequate local exhaust ventilation is not available or expo-	
Filter type	sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143 Particulates type (P)	

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state Colour Odour Odour Threshold	::	powder off-white No data available No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

according to Regulation (EC) No. 1907/2006



## **Ezetimibe / Atorvastatin Formulation**

Ver 2.6	sion	Revision Date: 09.04.2021		S Number: I89-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	Flamm	ability (solid, gas)	:	May form explos dling or other me	ive dust-air mixture during processing, han- eans.
	Flamm	ability (liquids)	:	No data available	e
		explosion limit / Upper ability limit	:	No data available	e
		explosion limit / Lower ability limit	:	No data available	e
	Flash p	point	:	Not applicable	
	Auto-ig	nition temperature	:	No data available	e
		position temperature composition tempera-	:	No data available	e
	рН		:	No data available	e
	Viscosi Visc	ity cosity, kinematic	:	No data available	e
	Solubil Wat	ity(ies) ter solubility	:	0.01 g/l	
	Partitio octano	n coefficient: n-	:	No data available	e
		r pressure	:	No data available	e
	Relativ	e density	:	No data available	e
	Density	/	:	No data available	e
	Relativ	e vapour density	:	No data available	e
		e characteristics ticle size	:	No data available	e
9.2	Other ir	nformation			
	Explosi	ives	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	e
	Molecu	ılar weight	:	No data available	e

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		9S Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	nical stability	IS.		
	ibility of hazardous rea		ons	
	dous reactions	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans. rong oxidizing agents.
10.4 Cond	litions to avoid			
Condi	tions to avoid	:	Heat, flames and Avoid dust forma	
	npatible materials			
Mater	ials to avoid		Oxidizing agents	
No ha	rdous decomposition p zardous decomposition 111: Toxicological in	pro	ducts are known.	
	nation on likely routes of		<b>as defined in Reg</b> Inhalation Skin contact Ingestion Eye contact	ulation (EC) No 1272/2008
	e toxicity assified based on availa	ble	·	
Comp	oonents:			
Atorv	astatin:			
Acute	oral toxicity	:	LD50 (Rat, male a	and female): > 5,000 mg/kg
			LD50 (Mouse, ma	le and female): > 5,000 mg/kg
Ezetir	nibe:			
Acute	oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg
			LD50 (Mouse): >	5,000 mg/kg
			LD50 (Dog): > 3,0	00 mg/kg
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	dermal toxicity	:	Remarks: No data	a available
	toxicity (other routes of istration)	:	LD50 (Rat): > 2,0 Application Route	
			LD50 (Mouse): > Application Route	1,000 - < 2,000 mg/kg : Intraperitoneal

according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014

: Rabbit

:

No skin irritation

### Skin corrosion/irritation

Not classified based on available information.

### **Components:**

#### Atorvastatin:

Species		
Result		

#### Ezetimibe:

Species	:	Rabbit
Result	:	No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### **Components:**

#### Atorvastatin:

Species	:	Rabbit
Method	:	Draize Test
Result	:	No eye irritation

#### Ezetimibe:

Species	:	Rabbit
Result	:	No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Components:**

#### Atorvastatin:

:	Maximisation Test
:	Skin contact
:	Guinea pig
:	negative
	:

### Ezetimibe:

Test Type	:	Maximisation Test
Species	:	Guinea pig
Result	:	negative

according to Regulation (EC) No. 1907/2006



sion	Revision Date: 09.04.2021	SDS Numb 26489-000	
Germ	cell mutagenicity		
Not cl	lassified based on av	ailable informati	on.
<u>Com</u>	ponents:		
Atory	vastatin:		
Geno	toxicity in vitro	Test sy	pe: reverse mutation assay stem: Salmonella typhimurium negative
		Test sy	pe: reverse mutation assay stem: Escherichia coli negative
		Test sy	pe: In vitro mammalian cell gene mutation test stem: Chinese hamster lung cells negative
		Test sy	pe: sister chromatid exchange assay stem: Chinese hamster lung cells negative
Geno	toxicity in vivo	Species Cell typ Applica	pe: In vivo micronucleus test :: Mouse e: Bone marrow ion Route: Oral negative
Ezeti	mibe:		
Geno	toxicity in vitro	Metabo	pe: Bacterial reverse mutation assay (AMES) lic activation: with and without metabolic activatio negative
		Test sy	pe: Chromosomal aberration stem: Human lymphocytes negative
Geno	toxicity in vivo	Species Cell typ Applica	pe: Micronucleus test :: Mouse e: Bone marrow ion Route: Oral negative
	nogenicity lassified based on av		-
	ponents:		
	vastatin:		
Speci Applic		: Mouse, : oral (ga : 2 Years	
NOAE			/kg body weight

according to Regulation (EC) No. 1907/2006



## **Ezetimibe / Atorvastatin Formulation**

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
LOAEL Result Target	Organs	: 400 mg/kg b : negative : Liver	ody weight
Exposi LOAEL	ation Route ure time	: Rat, female : oral (gavage : 2 Years : 100 mg/kg b : Musculo-ske	ody weight
Ezetim	iibe:		
	s ation Route ure time	: Rat, female : oral (feed) : 104 weeks : negative	
	s ation Route ure time	: Rat, male : oral (feed) : 104 weeks : negative	
	s ation Route ure time	: Mouse : oral (feed) : 104 weeks : negative	
-	ductive toxicity ssified based on ava	ilable information.	
Compo	onents:		
Atorva	statin:		
Effects	on fertility	Species: Rat Fertility: NO	ertility/early embryonic development , female AEL: 225 mg/kg body weight ffects on fertility
		Species: Rat Fertility: NO	ertility/early embryonic development , male AEL: 175 mg/kg body weight ffects on fertility
Effects ment	on foetal develop-	Result: No te	, female tal Toxicity: NOAEL: 20 mg/kg body weight eratogenic effects, Embryo-foetal toxicity aternal toxicity observed.

### Ezetimibe:

\_

according to Regulation (EC) No. 1907/2006



## **Ezetimibe / Atorvastatin Formulation**

Version 2.6	Revision Date: 09.04.2021		S Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
Effects	on fertility	:	Species: Rat, male Fertility: NOAEL: >	y/early embryonic development e and female > 1,000 mg/kg body weight on fertility, No fetotoxicity
Effects ment	on foetal develop-	:	Test Type: Develo Species: Rat Application Route: Developmental To Result: No advers	: Oral pxicity: NOAEL: > 1,000 mg/kg body weight
			Test Type: Develo Species: Rabbit Application Route: Developmental To Result: No advers	: Oral pxicity: NOAEL: > 1,000 mg/kg body weight

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

### Atorvastatin:

Exposure routes	:	Ingestion
Target Organs	:	Liver, muscle
Assessment	:	May cause damage to organs through prolonged or repeated
		exposure.

: Rat, male and female

: 70 mg/kg : oral (gavage) : 52 Weeks

: Liver

: Dog

: Liver

: 10 mg/kg

### **Repeated dose toxicity**

### **Components:**

### Atorvastatin:

Species LÖAEL Application Route Exposure time Target Organs

Species LOAEL Application Route:oral (gavage)Exposure time:104 Weeks Target Organs

### Ezetimibe:

Species	:	Dog
NOAEL	:	1,000 mg/kg
Application Route	:	Oral
Exposure time	:	90 d

according to Regulation (EC) No. 1907/2006



## **Ezetimibe / Atorvastatin Formulation**

Version 2.6	Revision Date: 09.04.2021		OS Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
Rema	arks	:	No significant a	adverse effects were reported
	EL cation Route sure time		Rat 1,500 mg/kg Oral 90 d No significant a	adverse effects were reported
	EL cation Route sure time		Mouse 500 mg/kg Oral 90 d No significant a	adverse effects were reported
	EL cation Route sure time	:	Dog 300 mg/kg Oral 1 yr No significant a	adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### **Components:**

#### Ezetimibe:

Not applicable

### **11.2 Information on other hazards**

### **Endocrine disrupting properties**

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

### Components:

Atorvastatin:		
Ingestion	Symptoms: muscle pain, Fatigue, stomach discomfo dominal pain, constipation, flatulence, liver function of	
Ezetimibe:		
Ingestion	Symptoms: Headache, Nausea, Vomiting, Diarrhoea lence, muscle pain, upper respiratory tract infection, pain, joint pain	

according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014

### **SECTION 12: Ecological information**

### 12.1 Toxicity

Components:		
Atorvastatin:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 200 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition
Toxicity to fish (Chronic tox- icity)	:	NOEC: 0.49 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC: 0.2 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
Ezetimibe:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 4 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l Exposure time: 96 h

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		0S Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
			Method: OECD To Remarks: No toxio	est Guideline 201 city at the limit of solubility
			mg/l Exposure time: 96 Method: OECD To	
Tox	icity to microorganisms	:	EC50 : > 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD To Remarks: No toxio	h ration inhibition
			NOEC : 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD To Remarks: No toxio	ation inhibition
Tox icity	icity to fish (Chronic tox- )	:	NOEC: 0.051 mg/ Exposure time: 33 Species: Pimepha Method: OECD To	3 d ales promelas (fathead minnow)
				d don variegatus (sheepshead minnow) city at the limit of solubility
aqu	icity to daphnia and other atic invertebrates (Chron- xicity)	:		
M-F toxic	actor (Chronic aquatic city)	:	1	
12.2 Per	sistence and degradabil	ity		
<u>Cor</u>	nponents:			
	<b>rvastatin:</b> degradability	:	Result: Not readily Biodegradation: 7 Exposure time: 28 Method: OECD Te	7.7 % 3 d
-	<b>timibe:</b> degradability	:	Result: Not readily Biodegradation: 6 Exposure time: 28	5.8 %

according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Versi 2.6	ion	Revision Date: 09.04.2021	-	DS Number: 6489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
	Stabilit	y in water	:	Hydrolysis: 50 %(4.5 d) Method: OECD Test Guideline 111	
12.3	Bioac	cumulative potential			
	Comp	onents:			
	Atorva	istatin:			
	Partitic octano	n coefficient: n- I/water	:	log Pow: 1.62	
	Ezetim	nibe:			
	Bioacc	umulation	:	Exposure time: 9 Bioconcentration	s macrochirus (Bluegill sunfish) 7 d factor (BCF): 173 est Guideline 305
	Partitic octano	n coefficient: n- l/water	:	log Pow: 4.36	
12.4	Mobili	ty in soil			
	Comp	onents:			
	Atorva	istatin:			
		ution among environ- compartments	:	log Koc: 2.84	
	Ezetim	nibe:			
		ution among environ- compartments	:		est Guideline 106
12.5	Result	ts of PBT and vPvB a	sse	ssment	
	Produ	<u>ct:</u>			
	Assess	sment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of

### 12.6 Endocrine disrupting properties

### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

according to Regulation (EC) No. 1907/2006



## **Ezetimibe / Atorvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014

### **SECTION 13: Disposal considerations**

#### **13.1 Waste treatment methods** Product Dispose of in accordance with local regulations. : According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Empty containers should be taken to an approved waste han-Contaminated packaging : dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

14.1 UN number or ID number				
ADN	:	UN 3077		
ADR	:	UN 3077		
RID	:	UN 3077		
IMDG	:	UN 3077		
ΙΑΤΑ	:	UN 3077		
14.2 UN proper shipping name				
ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)		
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)		
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)		
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)		
ΙΑΤΑ	:	Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Atorvastatin)		
14.3 Transport hazard class(es)				
ADN	:	9		
ADR	:	9		
RID	:	9		
IMDG	:	9		
ΙΑΤΑ	:	9		
14 4 Packing group				

according to Regulation (EC) No. 1907/2006



Vers 2.6	sion	Revision Date: 09.04.2021		9S Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014
		g group cation Code Identification Number		III M7 90 9	
	Hazard Labels	g group cation Code Identification Number restriction code		III M7 90 9 (-)	
		g group cation Code Identification Number	:	III M7 90 9	
	IMDG Packing Labels EmS C		:	III 9 F-A, S-F	
	aircraft	g instruction (cargo g instruction (LQ)	:	956 Y956 III Miscellaneous	
	Packing ger airc	g instruction (LQ)	:	956 Y956 III Miscellaneous	
14.5	i Enviro	nmental hazards			
	<b>ADN</b> Environ	mentally hazardous	:	yes	
	<b>ADR</b> Enviror	mentally hazardous	:	yes	
	<b>RID</b> Environ	mentally hazardous	:	yes	
	<b>IMDG</b> Marine	pollutant	:	yes	
		Passenger) mentally hazardous	:	yes	
	IATA (( Environ	Cargo) Imentally hazardous	:	yes	



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.6	09.04.2021	26489-00016	Date of first issue: 29.10.2014

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version
		are highlighted in the body of this document by two vertical lines.

according to Regulation (EC) No. 1907/2006



## Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021		S Number: 489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014		
Full tex	t of H-Statements					
H373		:	May cause damaged and cause damaged by the second s	ge to organs through prolonged or repeated wed.		
H410		:	: Very toxic to aquatic life with long lasting effects.			
H411				e with long lasting effects.		
Full tex	ct of other abbreviation					
Aquatic STOT F IE OEL	-	:		an toxicity - repeated exposure emical Agents and Occupational Exposure		
IE OEL	/ OELV - 8 hrs (TWA)	:		osure limit value (8-hour reference period)		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization: KECI - Korea Existing Chemicals Inventory: LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

#### **Classification of the mixture:**

### Classification procedure:

STOT RE 2

H373

Calculation method



## Ezetimibe / Atorvastatin Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 26489-00016	Date of last issue: 16.10.2020 Date of first issue: 29.10.2014	
Aqua	tic Chronic 2	H411	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN